Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Capicua transcriptional repressor pseudogene 10 (CICP10) is classified as a human pseudogene—a genomic DNA sequence similar to a known gene, but typically nonfunctional due to mutations that prevent normal protein-coding. It derives from the parental gene CIC, which encodes a high-mobility group box transcriptional repressor with important roles in development and disease. However, CICP10 itself does not code for a protein, does not act as a receptor, enzyme, or drug target, and currently lacks evidence for biological or therapeutic relevance. Pseudogenes like CICP10 may sometimes play regulatory roles as non-coding RNAs in human biology, but there is no direct evidence or established function for CICP10 in the literature at this time. CICP10 is not considered a therapeutic target and is an incorrect target if the query intent was to find a druggable protein or functional receptor. Research and clinical interest should be focused on the functional parental gene, Capicua transcriptional repressor (CIC), for target-related roles.
None, as it is a pseudogene
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Capicua transcriptional repressor pseudogene 10 (CICP10).